| Literature DB >> 23226600 |
Martina Beyrau1, Jennifer Victoria Bodkin, Sussan Nourshargh.
Abstract
Leucocytes form the principal cellular components of immunity and inflammation, existing as multiple subsets defined by distinct phenotypic and functional profiles. To date, this has most notably been documented for lymphocytes and monocytes. In contrast, as neutrophils are traditionally considered, to be short-lived, terminally differentiated cells that do not re-circulate, the potential existence of distinct neutrophil subsets with functional and phenotypic heterogeneity has not been widely considered or explored. A growing body of evidence is now challenging this scenario, and there is significant evidence for the existence of different neutrophil subsets under both physiological and pathological conditions. This review will summarize the key findings that have triggered a renewed interest in neutrophil phenotypic changes, both in terms of functional implications and consequences within disease models. Special emphasis will be placed on the potential pro- and anti-inflammatory roles of neutrophil subsets, as indicated by the recent works in models of ischaemia-reperfusion injury, trauma, cancer and sepsis.Entities:
Keywords: inflammation; neutrophil; neutrophil phenotype; neutrophil plasticity; neutrophil subset
Mesh:
Substances:
Year: 2012 PMID: 23226600 PMCID: PMC3513838 DOI: 10.1098/rsob.120134
Source DB: PubMed Journal: Open Biol ISSN: 2046-2441 Impact factor: 6.411
Molecules that characterize physiologically occurring neutrophil subsets. Shown are key molecules that are differentially expressed on subsets of neutrophils under physiological conditions and their possible functions. BM, bone marrow; GI, gastrointestinal; GPI, glycosyl-phosphatidylinositol; ICAM-1, intercellular adhesion molecule-1; Ig, immunoglobulin; PECAM-1, platelet endothelial cell adhesion molecule-1; RA, rheumatoid arthritis; rTEM, reverse transendothelial cell migration.
| protein | characteristics | expression in neutrophils | function in neutrophils |
|---|---|---|---|
| OLFM4 | — glycoprotein | — specific granules of 20–25% of human circulating neutrophils | — inhibits intracellular killing of bacteria via inhibition of cathepsin C |
| NB1 (CD177) | — GPI-anchored cell surface receptor | — about 30–70% of human circulating neutrophils | — binds with high-affinity to PECAM-1 |
| ICAM-1 (CD54) | — cell surface glycoprotein | — very low on circulating neutrophils | — binds integrins αLβ2 and αMβ2 |
| CXCR4 (CD184) | — chemokine receptor | — upregulated on senescent neutrophils | — upregulation aids sequestration of aged neutrophils back to the bone marrow |
| CXCR2 (CD182) | — chemokine receptor | — downregulated on senescent and rTEM neutrophils, and on neutrophils from aged mice | — downregulation impairs neutrophil migration into inflammatory sites |
Figure 1.Changes in neutrophil phenotype post-TEM. Summarized are molecular and functional changes reported in conjunction with neutrophil TEM/tissue infiltration and neutrophil reverse transendothelial migration through endothelial cells. The latter may involve movement of neutrophils within the transmigration pore in an abluminal-to-luminal direction or, under extreme conditions, migration from the subendothelial space back into the vascular lumen. FasL, Fas ligand; NET, neutrophil extracellular trap; TEM, transendothelial cell migration; TNF-R1, tumour necrosis factor receptor type 1.
Neutrophil subsets during pathological conditions. The table describes neutrophil subsets, including their phenotype and function, which have been identified in pathological conditions such as cancer, infection and inflammation in mice or humans. Subsets with a pro-inflammatory or anti-inflammatory phenotype are highlighted in italics and bold, respectively. IFN, interferon; IL, interleukin; i.v., intravenous; LDG, low-density granulocyte; LPS, lipopolysaccharide; MRSA, methicillin-resistant Staphylococcus aureus; PBMC, peripheral blood mononuclear cell; PMN, polymorphonuclear neutrophil; ROS, reactive oxygen species; SIRS, systemic inflammatory response syndrome; SLE, systemic lupus erythematosus; TAN, tumour-associated neutrophil; TGF, transforming growth factor; TLR, toll-like receptor.
| disease model | subset | occurrence | phenotype | proposed systemic effects |
|---|---|---|---|---|
| murine subcutaneous tumours [ | — | — | — | |
| — | — | — | ||
| MRSA infection in mice [ | — | — | — | |
| — | — | — | ||
| human experimental endotoxemia [ | — | — | — | |
| — | — | — | ||
| — | — | — | ||
| SLE patients [ | — | — | — |